Comorbidities of naïve (n=227) and biological agents failure (n=381) in patients with PsA
Comorbidities | Group A | Group B | P value |
Metabolic syndrome | 14 (6.2%) | 61 (16.1%) | 0.03 |
Hypertension | 74 (32.6%) | 164 (43.1%) | 0.04 |
Ischaemic heart disease | 10 (4.4%) | 36 (9.5%) | 0.04 |
Dyslipidaemia | 45 (19.8%) | 117 (30.7%) | 0.03 |
Hyperuricaemia | 33 (14.5%) | 69 (18.1%) | ns |
Type II diabetes | 13 (5.7%) | 46 (12.1%) | 0.02 |
Gastritis, gastric ulcer or dyspeptic disorders | 24 (10.6%) | 52 (13.6%) | ns |
Liver disease (eg, steatosis) | 16 (7.1%) | 53 (13.9%) | 0.05 |
Pneumopathies | 11 (4.8%) | 30 (7.9%) | ns |
Thyroid disorder | 25 (11.1%) | 53 (13.9%) | ns |
Osteoporosis | 15 (6.6%) | 36 (9.5%) | ns |
Kidney failure | 3 (1.3%) | 10 (2.6%) | ns |
Depression | 16 (7.1%) | 56 (14.7%) | 0.05 |
Fibromyalgia | 29 (12.8%) | 73 (19.2%) | ns |
Neurological disorders (such as neuropathy) | 8 (3.5%) | 28 (7.4%) | ns |
Positive Mantoux RB skin test or Quantiferon TB Gold test | 12 (5.3%) | 28 (7.4%) | ns |
Previous hepatitis B | 14 (6.2%) | 36 (9.5%) | ns |
Previous hepatitis C | 3 (1.3%) | 11 (2.9%) | ns |
Previous eradicated cancer | 7 (3.1%) | 24 (6.3%) | 0.05 |
P≤0.05. Values were computed by means of a χ2 test (for proportion).
Group A=naïve to TNF inhibitors; group B=TNF inhibitors and IL-12/23 inhibitors failure.
Data are expressed as frequency (absolute number and percentage).
The italics character was used to mark the p value.
IL, interleukin; ns, not statistically significant; PsA, psoriatic arthritis; TNF, tumour necrosis factor.